5 June 2020 - Regulatory submissions based on positive data from Phase III VICTORIA study recently published in the New England Journal of Medicine.

Bayer today announced the submission of two regulatory applications seeking the approval of vericiguat in the EU and Japan. Vericiguat is an investigational oral, once-daily, first-in-class soluble guanylate cyclase stimulator being developed to treat patients with symptomatic chronic heart failure with an ejection fraction less than 45% who have had a previous worsening heart failure event (defined as heart failure hospitalization or receiving an intravenous diuretic for heart failure without hospitalization) in combination with available heart failure therapies. 

Vericiguat is being jointly developed with MSD.

Read Bayer press release